Printed from Voxsanity (voxsanity.com.au) — NCT02912897 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Multiple Sclerosis
Phase 1 Multiple Sclerosis Trial, Recruiting
NCT02912897
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged over 18 and up to 45 years old
- People who have had a first neurological episode (such as optic neuritis, a spinal cord problem, or a brainstem/cerebellar problem) that is consistent with damage to the protective covering of nerves (demyelination)
- People whose MRI scan shows lesions (areas of damage) in at least two specific locations in the brain or spinal cord, meeting 2017 McDonald criteria for spread in space
- People whose MRI shows both an active lesion (one that lights up with contrast dye) and an inactive lesion at the same time, suggesting the condition may have occurred at more than one point in time
- People whose spinal fluid (CSF) test shows specific bands called oligoclonal bands (OCBs), which can indicate nervous system inflammation (confirm with trial site)
- People with an EDSS disability score below 3 (a measure of neurological disability — confirm with trial site)
- People covered by health insurance (social security)
- People whose symptoms began within 60 days before joining the trial
- People who have tested negative for HIV, HTLV, Hepatitis B, Hepatitis C, and Syphilis within the 30 days before joining
- People who have tested positive for Epstein-Barr virus (EBV) exposure
- People with a white blood cell count above 750/mm³
- People with a negative pregnancy test
Who may not be able to join:
- People who have already been diagnosed with clinically definite multiple sclerosis
- People known to have HIV, HTLV, Hepatitis A, B, or C, or Syphilis, or who have an active, uncontrolled infection (bacterial, viral, parasitic, or fungal)
- People with a white blood cell count below 750/mm³
- People who are pregnant or breastfeeding
- People of childbearing potential who are unwilling to use an effective method of contraception during the trial
- People who wish to become pregnant during the course of the trial
- People under legal guardianship
- People currently participating in another clinical trial
- People with a mental health or psychiatric condition that would prevent them from understanding the trial
- People with an unstable medical condition, or any health condition that the trial investigator determines could affect their safety
- People with a stable condition currently being treated with any form of immunotherapy
- People who have had cancer within the past 5 years, or who have an ongoing cancer (except for certain skin cancers that have been surgically removed and cured, or cervical cancer in situ)
- People who are unable to follow the trial's procedures and requirements
- People who cannot have an MRI scan, or who have a known allergy or sensitivity to contrast dye used in MRI scans
- People currently taking immunosuppressive medications, including oral or systemic corticosteroids (steroid medicines)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Phone: + 33 (0)2 40 16 52 00
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 1
Sponsor
Registry
ClinicalTrials.gov
Start date
26 January 2021
Est. completion
1 November 2028
Where this trial is recruiting
🇫🇷 France
Primary endpoints
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.